Search results for "inflammatory"

showing 10 items of 1845 documents

FRI0150 Mtor blockade by rapamycin decreases arthritis and spondylitis development and severity in hla-b27 transgenic rats

2018

Career situation of first and presenting author Student for a master or a PhD. Introduction TNF and IL-17A have been demonstrated as key inflammatory cytokines in Spondyloarthritis (SpA), whereas targeting bone remodeling remains an unmet clinical need in SpA. The mammalian target of rapamycin (mTOR) regulates IL-17 expression and osteogenesis and could therefore be a promising therapeutic target in SpA. Objectives To investigate if blockade of mTOR with rapamycin inhibits the pathological processes in inflammation and bone in SpA. Methods Cytokines were measured by ELISA in the supernatant from SpA patient PBMCs stimulated with anti-CD3/CD28, with various concentrations of rapamycin. SpA F…

musculoskeletal diseases030203 arthritis & rheumatologyHLA-B27business.industryArthritis030209 endocrinology & metabolismInflammationPharmacologymedicine.diseaseBlockadeProinflammatory cytokineBone remodeling03 medical and health sciences0302 clinical medicinemedicineTumor necrosis factor alphamedicine.symptombusinessPI3K/AKT/mTOR pathwayFRIDAY, 15 JUNE 2018
researchProduct

Comparison of the acute effects of anti-TNF-alpha drugs on a uveitis experimental model.

2010

To compare histopathological and biochemical effects of the anti-TNF-alpha drugs adalimumab and infliximab in a uveitis experimental model.Histopathological evaluation was performed 24 h after endotoxin (200 microg into the footpad) and drug administration, as well as biochemical analysis of oxidative stress-related markers in the aqueous humor.Severe inflammation was found in rat anterior chamber of the eye 24 h after endotoxin. Only infliximab administration partially prevented the endotoxin-induced disruption of the blood-aqueous barrier, as well as the increase in Rantes and MCP-1 concentration in aqueous humor. Both drugs ameliorated the histopathological score after endotoxin. Biochem…

musculoskeletal diseasesAcute effectsMaleBlood-Aqueous BarrierTime FactorsAnti-Inflammatory AgentsInflammationmedicine.disease_causeAntibodies Monoclonal HumanizedAqueous HumorUveitisAdalimumabImmunology and AllergyMedicineAnimalsskin and connective tissue diseasesCells Culturedbiologybusiness.industryTumor Necrosis Factor-alphaAdalimumabAntibodies Monoclonalmedicine.diseaseInfliximabInfliximabRatsOphthalmologyDisease Models AnimalOxidative StressTreatment OutcomeRats Inbred LewImmunologyMonoclonalbiology.proteinAntibodymedicine.symptombusinessOxidative stressUveitismedicine.drugOcular immunology and inflammation
researchProduct

Adalimumab in active ulcerative colitis: A “real-life” observational study

2013

Abstract Background and aims The effectiveness of adalimumab in the treatment of ulcerative colitis is under debate. Although controlled trials have shown that adalimumab is significantly better than placebo, the absolute clinical benefit is modest. We report data on the effectiveness of adalimumab in a cohort of ulcerative colitis patients treated in 22 Italian centres. Methods All patients with active disease treated with adalimumab were retrospectively reviewed. Co-primary endpoints were clinical remission at weeks 4, 12, 24 and 54. Secondary endpoints were sustained clinical remission, steroid discontinuation, endoscopic remission and need for colectomy. Results Eighty-eight patients we…

musculoskeletal diseasesAdultMaleAdalimumab “Real-life” study Ulcerative colitismedicine.medical_specialtymedicine.medical_treatmentIBDAnti-Inflammatory AgentsAdalimumab; “Real-life” study; Ulcerative colitisAntibodies Monoclonal HumanizedPlaceboCohort StudiesYoung AdultRefractoryAdrenal Cortex HormonesInternal medicineAdalimumabmedicineHumansskin and connective tissue diseases“Real-life” studyRetrospective StudiesColectomySettore MED/12 - GastroenterologiaHepatologybusiness.industryRemission InductionSettore MED/09 - MEDICINA INTERNAGastroenterologyAdalimumabmedicine.diseaseUlcerative colitishumanitiesInfliximabSurgeryDiscontinuationTreatment OutcomeUlcerative colitisCohortColitis UlcerativeDrug Therapy CombinationFemalebusinessmedicine.drug
researchProduct

Tumour necrosis factor   in rheumatoid arthritis and osteoarthritis patients in blood serum and synovial fluid

2010

Rheumatoid arthritis (RA) is a chronic autoimmune disease of unknown cause which affects the ability of elderly people to work. There is strong evidence to suggest that inflammatory mediators such as tumour necrosis factor α (TNFα) and interleukin 1 (IL1) have a critical role in the pathogenesis of RA. Biological treatment blocks pathological pathways in the actions of these proinflammatory cytokines. The aim of this study was …

musculoskeletal diseasesAutoimmune diseasebusiness.industryImmunologyInterleukinmedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokinePathogenesisBlood serumRheumatologyRheumatoid arthritisImmunologymedicineImmunology and AllergySynovial fluidTumor necrosis factor alphabusinessAnnals of the Rheumatic Diseases
researchProduct

Targeting of the transcription factor STAT4 by antisense phosphorothioate oligonucleotides suppresses collagen-induced arthritis

2007

Abstract The transcription factor STAT4 mediates signals of various proinflammatory cytokines, such as IL-12, IL-15, and IL-23, that initiate and stabilize Th1 cytokine production. Although Th1 cytokine production has been suggested to play a major pathogenic role in rheumatoid arthritis, the role of STAT4 in this disease is poorly understood. In this study, we demonstrate a key functional role of STAT4 in murine collagen-induced arthritis (CIA). In initial studies we found that STAT4 expression is strongly induced in CD4+ T cells and to a lesser extent in CD11b+ APCs during CIA. To analyze the role of STAT4 for arthritis manifestation, we next investigated the outcome of interfering with S…

musculoskeletal diseasesImmunologyAntigen-Presenting CellsCodon InitiatorArthritisBiologyProinflammatory cytokineArthritis RheumatoidPathogenesisMiceimmune system diseasesmedicineAnimalsImmunology and Allergyskin and connective tissue diseasesSTAT4Cells CulturedMice KnockoutMice Inbred BALB CCD11b Antigenhemic and immune systemsOligonucleotides AntisenseSTAT4 Transcription FactorTh1 CellsThionucleotidesmedicine.diseaseArthritis ExperimentalIntegrin alpha MRheumatoid arthritisImmunologybiology.proteinExperimental pathologyTumor necrosis factor alpha
researchProduct

Sicilian pistachio (Pistacia vera L.) nut inhibits expression and release of inflammatory mediators and reverts the increase of paracellular permeabi…

2014

Background Dietary approaches to control inflammatory bowel diseases (IBD) may include proanthocyanidin-rich foods. Our previous research showed that a hydrophilic extract from Sicilian pistachio nut (HPE) contains sub- stantial amounts of proanthocyanidins and possesses anti- inflammatory activities. Purpose We studied the effects of HPE and of its poly- meric proanthocyanidin fraction (PPF) in a cell model that simulated some conditions of IBD, consisting of interleukin (IL)-1b-stimulated Caco-2 cells. Methods HPE was prepared by Pistacia vera L. nuts, and PPF was isolated from HPE by adsorbance chromatogra- phy. Proanthocyanidins were quantified as anthocyanidins after acidic hydrolysis.…

musculoskeletal diseasesPistachio nut Inflammation Intestinal epithelium Polyphenols Proanthocyanidinscongenital hereditary and neonatal diseases and abnormalitiesCellInterleukin-1betaAnti-Inflammatory AgentsMedicine (miscellaneous)BiologyPharmacologyPermeabilityCell membraneSettore BIO/10 - BiochimicamedicineHumansNutsProanthocyanidinsViability assayIntestinal MucosaCell ProliferationNutrition and DieteticsPistaciaInterleukin-6Interleukin-8NF-kappa BEpithelial Cellsbiology.organism_classificationIntestinal epitheliumIntestinesmedicine.anatomical_structureProanthocyanidinBiochemistryCaco-2Cyclooxygenase 2Paracellular transportPistaciaCaco-2 Cells
researchProduct

Hip viscosupplementation under ultra-sound guidance riduces NSAID consumption in symptomatic hip osteoarthritis patients in a long follow-up. Data fr…

2011

Introduction: Non-steroidal anti-inflammatory drugs (NSAIDs) consumption is strictly related to a high gastrointestinal and cardiovascular mortality and morbidity rate. Osteoarthritis Research Society International (OARSI) recommendations in patients with symptomatic hip or knee OA stated that NSAIDs should be used at the lowest effective dose but their long-term use should be avoided if possible. OARSI guidelines for the treatment of the hip OA include the use of viscosupplementation, which aims to restore physiological and rheological features of the synovial fluid. Objective: Aim of this multicentric, open and retrospective study is to investigate if NSAID consumption may be reduced by t…

musculoskeletal diseaseshipultrasoundintra-articular injection; nsaid; hyaluronic acid; hip; ultrasound; osteoarthritisAnti-Inflammatory Agents Non-SteroidalMiddle AgedHip viscosupplementation ultra-sound guidanceOsteoarthritis HipInjections Intra-ArticularosteoarthritisSettore MED/33 - Malattie Apparato LocomotoreHumansUltrasonicsRegistriesHyaluronic Acidnsaidintra-articular injectionAgedFollow-Up StudiesPain MeasurementRetrospective StudiesUltrasonography
researchProduct

Patología articular en la enfermedad inflamatoria intestinal

2005

The joint disorders taxonomically included in the group of seronegative spondyloarthropathies under the generic name of enteropathic arthropathy represent the most frequent extra-intestinal manifestation of inflammatory bowel disease (IBD), affecting 33% of patients. Their frequency is similar to that of ulcerative colitis and Crohn's disease. Enteropathic arthropathy consists of two main joint alterations, peripheral and axial arthritis, as well as a variable group of other peri-articular disorders. Type 1, or pauciarticular, peripheral arthritis generally coincides with IBD exacerbations, while type 2, or polyarticular, peripheral arthritis follows an independent course from IBD. Axial in…

musculoskeletal diseasesmedicine.medical_specialtyAnkylosing spondylitisHepatologyEnteropathic arthropathybusiness.industryGastroenterologySacroiliitisArthritismedicine.diseaseGastroenterologyInflammatory bowel diseaseAsymptomaticUlcerative colitisdigestive system diseasesInfliximabInternal medicinemedicinemedicine.symptombusinessmedicine.drugGastroenterología y Hepatología
researchProduct

Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study

2017

AIM To assess the impact of short infliximab (IFX) infusion on hospital resource utilization and costs. METHODS All inflammatory bowel diseases (IBD) patients who received IFX 1 h infusion from March 2007 to September 2014 in eight centers from Southern Italy were included in the analysis. Demographic, clinical and infusion related data were collected. The potential benefits related to the short infusion protocol were assessed both in terms of time saving and increased infusion unit capacity. In addition, indirect patient-related cost savings were evaluated. RESULTS One hundred and twenty-five patients were recruited (64 with ulcerative colitis and 61 with Crohn’s disease). Median duration …

musculoskeletal diseasesmedicine.medical_specialtyObservational StudyCost savings03 medical and health sciences0302 clinical medicineInternal medicinemedicineIn patient030212 general & internal medicineEconomic impact analysisskin and connective tissue diseasesProtocol (science)business.industryInflammatory Bowel DiseasesOne-hour infusionInfliximabInfliximabMulticenter studyCost savingsstomatognathic diseasesEconomic impactMulticenter studyPhysical therapy030211 gastroenterology & hepatologybusinessmedicine.drugWorld Journal of Gastrointestinal Pharmacology and Therapeutics
researchProduct

MINIMIZING INFLIXIMAB TOXICITY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

2008

Abstract Background Infliximab is a widely used biological agent for the treatment of inflammatory bowel disease, and has a favorable risk/benefit ratio. Aim It is useful to know that patients treated with infliximab are exposed to developing adverse events that could be reduced with a prudent and a rational clinical approach and by optimizing the treatment protocol. Methods PubMed (including Epub) was searched in October 2006 and again in March 2007. Results The high immunogenic potential of infliximab determines the antibodies that inhibit the effect of infliximab and the appearance of subsequent acute and delayed infusion reactions. Infliximab has an immunomodulatory effect, thus increas…

musculoskeletal diseasesmedicine.medical_specialtyTuberculosisInflammatory bowel diseaseGastroenterologyDrug Administration SchedulePharmacotherapyimmune system diseasesInternal medicinemedicineHumansImmunologic Factorsskin and connective tissue diseasesAdverse effectClinical Trials as TopicHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyAntibodies Monoclonalmedicine.diseaseInflammatory Bowel DiseasesInfliximabInfliximabLymphomastomatognathic diseasesHeart failureToxicityDrug Therapy CombinationbusinessImmunosuppressive Agentsmedicine.drug
researchProduct